ELSALYS BIOTECH is a pharmaceutical company which develops new generation antibodies to modulate the immune system of patients with cancer or rare haematological diseases.
Its mission is at the heart of personalised and precision medicine where the ultimate goal is to increase the proportion of responders to new treatments.
Today ELSALYS BIOTECH is conducting 5 proprietary development programs including Inolimomab (LEUKOTAC®), an immunotherapy antibody that has recently demonstrated its clinical superiority in Phase 3 in an orphan disease with very poor prognosis: steroid-resistant acute Graft-versus-Host Disease.
The company is acting today in 3 main medical fields :
Discover our latest news regarding our pipeline, our partnerships and more
By continuing to browse this website, you agree to the use of such cookies.